Do Patient Preferences Align With Value Frameworks? A Discrete-Choice Experiment of Patients With Breast Cancer

被引:3
|
作者
Hollin, Ilene L. [2 ]
Gonzalez, Juan Marcos [1 ]
Buelt, Lisabeth [3 ]
Ciarametaro, Michael [3 ]
Dubois, Robert W. [3 ]
机构
[1] Duke Univ, Sch Med, 2400 Pratt St, Durham, NC 27705 USA
[2] Temple Univ, Coll Publ Hlth, Philadelphia, PA USA
[3] Natl Pharmaceut Council, Washington, DC USA
关键词
breast cancer; discrete-choice experiment; value frameworks;
D O I
10.1177/2381468320928012
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Purpose. Assess patient preferences for aspects of breast cancer treatments to evaluate and inform the usual assumptions in scoring rubrics for value frameworks. Methods. A discrete-choice experiment (DCE) was designed and implemented to collect quantitative evidence on preferences from 100 adult female patients with a self-reported physician diagnosis of stage 3 or stage 4 breast cancer. Respondents were asked to evaluate some of the treatment aspects currently considered in value frameworks. Respondents' choices were analyzed using logit-based regression models that produced preference weights for each treatment aspect considered. Aggregate- and individual-level preferences were used to assess the relative importance of treatment aspects and their variability across respondents. Results. As expected, better clinical outcomes were associated with higher preference weights. While life extensions with treatment were considered to be most important, respondents assigned great value to out-of-pocket cost of treatment, treatment route of administration, and the availability of reliable tests to help gauge treatment efficacy. Two respondent classes were identified in the sample. Differences in class-specific preferences were primarily associated with route of administration, out-of-pocket treatment cost, and the availability of a test to gauge treatment efficacy. Only patient cancer stage was found to be correlated with class assignment (P = 0.035). Given the distribution of individual-level preference estimates, preference for survival benefits are unlikely to be adequately described with two sets of preference weights. Conclusions. Although value frameworks are an important step in the systematic evaluation of medications in the context of a complex treatment landscape, the frameworks are still largely driven by expert judgment. Our results illustrate issues with this approach as patient preferences can be heterogeneous and different from the scoring weights currently provided by the frameworks.
引用
收藏
页数:10
相关论文
共 50 条
  • [21] Patient and physician preferences for anticancer drugs for the treatment of metastatic colorectal cancer: a discrete-choice experiment
    Gonzalez, Juan Marcos
    Ogale, Sarika
    Morlock, Robert
    Posner, Joshua
    Hauber, Brett
    Sommer, Nicolas
    Grothey, Axel
    CANCER MANAGEMENT AND RESEARCH, 2017, 9 : 149 - 158
  • [22] PATIENT PREFERENCES DO MATTER: A DISCRETE CHOICE EXPERIMENT (DCE) CONDUCTED WITH BREAST CANCER PATIENTS IN SIX EUROPEAN COUNTRIES
    Stamuli, E.
    Corry, S.
    Hatzikou, M.
    Foss, P.
    VALUE IN HEALTH, 2022, 25 (01) : S239 - S239
  • [23] Treatment preferences of patients with early rheumatoid arthritis: a discrete-choice experiment
    Hazlewood, Glen S.
    Bombardier, Claire
    Tomlinson, George
    Thorne, Carter
    Bykerk, Vivian P.
    Thompson, Andrew
    Tin, Diane
    Marshall, Deborah A.
    RHEUMATOLOGY, 2016, 55 (11) : 1959 - 1968
  • [24] Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
    Hazlewood, Glen S.
    Bombardier, Claire
    Tomlinson, George A.
    Thorne, Carter
    Bykerk, V. P.
    Thompson, Andrew
    Tin, Diane
    Marshall, Deborah
    ARTHRITIS & RHEUMATOLOGY, 2015, 67
  • [25] Attributes for a discrete-choice experiment on preferences of patients for oncology pharmacy consultations
    Damerval, Margaux
    Bennani, Mohammed
    Rioufol, Catherine
    Omrani, Selim
    Riboulet, Margaux
    Etienne-Selloum, Nelly
    Saint-Ghislain, Audrey
    Leenhardt, Fanny
    Schmitt, Antonin
    Simon, Nicolas
    Clairet, Anne-Laure
    Meurisse, Aurelia
    Nerich, Virginie
    SUPPORTIVE CARE IN CANCER, 2024, 32 (05)
  • [26] Patient preferences for metastatic renal cell carcinoma treatments: a discrete-choice experiment
    Gonzalez, Juan M.
    Doan, Justin
    Gebben, David J.
    Fishman, Mayer
    BJU INTERNATIONAL, 2016, 118 : 22 - 23
  • [27] Treatment Preferences of Patients with Early Rheumatoid Arthritis: A Discrete-Choice Experiment
    Hazlewood, Glen
    Marshall, Deborah
    Tomlinson, George
    Thorne, Carter
    Thompson, Andrew
    Bykerk, Vivian
    Tin, Diane
    Bombardier, Claire
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (07) : 1265 - 1266
  • [28] A discrete-choice experiment to assess treatment modality preferences of patients with depression
    Lokkerbol, Joran
    Geomini, Amber
    van Voorthuijsen, Jule
    van Straten, Annemieke
    Tiemens, Bea
    Smit, Filip
    Risseeuw, Anneriek
    Hiligsmann, Mickael
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (02) : 178 - 186
  • [29] PATIENTS' PREFERENCES IN FUNCTIONAL DYSPEPSIA AND MOTILITY DISORDER: A DISCRETE-CHOICE EXPERIMENT
    Muehlbacher, A. C.
    Sadler, A.
    Kaczynski, A.
    VALUE IN HEALTH, 2016, 19 (03) : A316 - A316
  • [30] Patient preferences for maintenance therapy in Crohn's disease: A discrete-choice experiment
    Hazlewood, Glen S.
    Pokharel, Gyanendra
    Deardon, Robert
    Marshall, Deborah A.
    Bombardier, Claire
    Tomlinson, George
    Ma, Christopher
    Seow, Cynthia H.
    Panaccione, Remo
    Kaplan, Gilaad G.
    PLOS ONE, 2020, 15 (01):